Market Access Call Competence -training program

Pharma market is rapidly changing, and a new broad base of stakeholders is impacting the uptake and use of pharmaceutical products. In Europe, breakthrough innovations can obtain marketing approval via Prime Fast Track program. New innovations tend to have a high price tag and at launch from the payer’s perspective, there is often significant uncertainty of the clinical outcomes in real life.

Cost-effectiveness has supplemented the established notions of safety, efficacy and quality as a further requirement to secure market access. Common consensus is that the traditional pharma sales model is no longer sufficient since engaging with payers and other budget holders require a different approach compared to the traditional industry methodology. Market Access Call Competence training program is designed in collaboration with pharma companies and is carried out by Medaffcon’s senior specialists.

Upon completing the program you will be able to:

  • Understand the implications your product has on the wider healthcare market and the operating units within it.
  • Understand the impact that the changing decision-making processes in healthcare will have on your product.
  • Prepare a positive and constructive approach so that the healthcare environment supports the uptake of your product.
  • Communicate the value of your product to the different stakeholders who influence uptake.

 

The objective of the program is to enhance the necessary skills and capabilities of Field Based Execution of Market Access Strategy of key customer-facing people in pharma companies and to execute a company-specific strategically important Market Access project.

 

The program covers the following topics:

  • Pharma environment in Finland; Policy and stakeholders
  • Price and reimbursement application processes
  • Hospital tendering processes
  • Key elements of Health Economics
  • Real World Evidence; Sources and use in practice
  • Patient access Schemes and Risk Sharing Agreements in hospitals and retail market
  • The use of Health Economics and RWE in negotiations

 

Download a brochure of the Market Access Call Competence training program and contact our experts for more information!

”This training course gives us a very broad and comprehensive understanding of the changing business environment in pharma and health care in Finland. in Today’s world, it’s not anymore enough to just know your product- and therapy area; one must also understand the operative principles of health care from the perspectives of the payer and society. ”
Participant
”Training in small groups works very well and enables an interactive atmosphere and facilitates a lot of discussions. The trainers at Medaffcon are top subject matter experts in Finland. Pre-class materials are available well before the training days and the company-specific project is mentored by Medaffcon.”
Participant
”Extremely good course, I recommend to anyone working with Key Opinion Leaders and/or decision makers at health care district level.”
Participant

We are more than happy to tell you more!!

Elisa Tyynysniemi
Scientific Project Manager

Contact us

Our Market Access Call Competence Experts:

Elisa Tyynysniemi
Scientific Project Manager

Elisa Tyynysniemi

Scientific Project Manager
M.Sc. (Pharmaceutical Science)

+358 40 8394 369 LinkedIn

Elisa started at Medaffcon in January 2015 as a Scientific Project Manager. Previously, Elisa has worked in drug safety unit at Novo Nordisk A/S in Copenhagen as well as sales permit related tasks in the Finnish Medicines Agency Fimea. Working at the Department of Pathology of the University of Turku, Elisa has also gained several years of experience in medical research and in working in a hospital environment.

Elisa has completed a Master’s degree in a programme for international drug development at the University of Copenhagen. She completed her Master’s thesis at Novo Nordisk A/S headquarters in Copenhagen. Elisa also holds a Bachelor of Science degree at the University of Turku in Biomedicine. Therefore, she has completed studies in Medicine, Natural Sciences, Pharmacy and Economics.

Due to her strong theoretical background and work experience, Elisa has wide understanding of the objectives of drug development both from the industrial and authority perspectives. Elisa is particularly interested in developing new medicinal treatment and improving therapeutic value. She is also excited about working with multifunctional teams and constructing seamless cooperation between different interest groups.


Jarmo Hahl
Managing Director

Jarmo Hahl

Managing Director
M.Sc. (Economics)

+358 40 139 4001 LinkedIn

Jarmo joined Medaffcon as a Partner and Managing Director in 2010, after previously working in different positions in the pharmaceutical industry for eight years. Jarmo holds a comprehensive understanding of the pharmaceutical field: he has worked in several expert and leading positions, e.g. as a Health Economic Expert, Head of a Pricing and Reimbursement Unit and as a Director of Health Economics and Market Access teams. Before moving to the pharmaceutical industry, Jarmo had a permanent position in Turku School of Economics and he worked as a researcher at Turku University Hospital.

Due to his background, Jarmo has a strong knowledge of how new health technological innovations can meet the requirements and expectations of authorities, markets and customers. Medaffcon also benefits from his comprehensive experience in Health Economics and its applications from the perspective of research and commercialisation. In addition, he has wide-ranging understanding of the constantly changing operational environment.

Jarmo deems Market Access as multidisciplinary and crucial to business, which makes it an extremely interesting field of operation.


Kalle Snicker
Sr. Market Access Specialist

Kalle Snicker

Sr. Market Access Specialist
M.Sc.

+358 400 526597 LinkedIn

Kalle Snicker joined Medaffcon’s team in September 2017. Kalle has worked a total of 26 years in the pharmaceutical industry; 16 years in cardiovascular and 10 years in oncology therapeutic areas. Along the years, he has gained experience in leading positions in sales and marketing, in running the Baltic business unit, and in recent years, in leading the oncology market access functions at Novartis.

Kalle’s principle has always been to work for the benefit of the patient, regardless of the position he is working in. Kalle’s strengths include his extensive and comprehensive view on how the industry functions as well as his ability to predict how future challenges can be considered and how the best possible result for the patient can be achieved in a new operational environment. Kalle is true a solver of difficult situations.